文献速递泌尿男性生殖肿瘤

奥拉帕利联合阿比特龙对比安慰剂联合阿比特龙治疗转移性去势抵抗性前列腺癌(PROpel):随机双盲3期试验最终预设总生存结果

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2023-09-12

PROpel研究在126个中心、17个国家入组未经HRRm选择的初治mCRPC患者,随机接受奥拉帕利联合阿比特龙或安慰剂联合阿比特龙。最终预设总生存分析显示两组中位总生存无显著差异(42.1个月 vs 34.7个月,HR 0.81,95%CI 0.67-1.00,p=0.054)。

要点

  • 奥拉帕利联合阿比特龙组中位总生存42.1个月,安慰剂联合阿比特龙组34.7个月,差异未达统计学显著(HR 0.81,95%CI 0.67-1.00,p=0.054)。
  • 最常见的3-4级不良事件为贫血,奥拉帕利组64例(16%) vs 安慰剂组13例(3%)。
  • 严重不良事件奥拉帕利组161例(40%) vs 安慰剂组126例(32%);安慰剂组1例间质性肺病死亡被认为与治疗相关。

核心结论

  • 在最终预设分析中,奥拉帕利联合阿比特龙组与安慰剂联合阿比特龙组的总生存无显著差异。

研究设计与样本

  • 随机、双盲、3期试验,在17个国家126个中心开展。
  • 入组年龄≥18岁、ECOG体能状态0-1、预期寿命≥6个月、未经mCRPC系统治疗且未按HRRm状态选择的mCRPC患者。
  • 按1:1中央随机分配至阿比特龙醋酸酯(口服1000 mg每日一次)联合泼尼松或泼尼松龙,加奥拉帕利(口服300 mg每日两次)或安慰剂。
  • 分层因素为转移部位和转移性激素敏感性癌阶段是否接受过多西他赛。
  • 共筛查1103例,随机分配奥拉帕利联合阿比特龙组399例、安慰剂联合阿比特龙组397例。

主要发现

  • 总生存中位随访时间(删失数据患者):奥拉帕利联合阿比特龙组36.6个月(IQR 34.1-40.3),安慰剂联合阿比特龙组36.5个月(IQR 33.8-40.3)。
  • 中位总生存:奥拉帕利联合阿比特龙组42.1个月(95%CI 38.4-未达到),安慰剂联合阿比特龙组34.7个月(95%CI 31.0-39.3),HR 0.81(95%CI 0.67-1.00),p=0.054。
  • 最常见3-4级不良事件为贫血:奥拉帕利联合阿比特龙组64例(16%,共398例),安慰剂联合阿比特龙组13例(3%,共396例)。
  • 严重不良事件:奥拉帕利联合阿比特龙组161例(40%),安慰剂联合阿比特龙组126例(32%)。
  • 安慰剂联合阿比特龙组1例间质性肺病死亡被认为与治疗相关。

关键数值与推荐

  • 总生存为主要次要终点,预设最终分析α阈值为0.0377(双侧),在意向治疗人群中评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PROpel met its primary endpoint showing statistically significant improvement in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus abiraterone in patients with first-line metastatic castration-resistant prostate cancer (mCRPC) unselected by homologous recombination repair mutation (HRRm) status, with benefit observed in all prespecified subgroups. Here we report the final prespecified overall survival analysis. METHODS: This was a randomised, double-blind, phase 3 trial done at 126 centres in 17 countries worldwide. Patients with mCRPC aged at least 18 years, Eastern Cooperative Oncology Group performance status 0-1, a life expectancy of at least 6 months, with no previous systemic treatment for mCRPC and unselected by HRRm status were randomly assigned (1:1) centrally by means of an interactive voice response system-interactive web response system to abiraterone acetate (orally, 1000 mg once daily) plus prednisone or prednisolone with either olaparib (orally, 300 mg twice daily) or placebo. The patients, the investigator, and study centre staff were masked to drug allocation. Stratification factors were site of metastases and previous docetaxel at metastatic hormone-sensitive cancer stage. Radiographic progression-free survival was the primary endpoint and overall survival was a key secondary endpoint with alpha-control (alpha-threshold at prespecified final analysis: 0·0377 [two-sided]), evaluated in the intention-to-treat population. Safety was evaluated in all patients who received at least one dose of a study drug. This study is registered with ClinicalTrials.gov, NCT03732820, and is completed and no longer recruiting. FINDINGS: Between Oct 31, 2018 and March 11, 2020, 1103 patients were screened, of whom 399 were randomly assigned to olaparib plus abiraterone and 397 to placebo plus abiraterone. Median follow-up for overall survival in patients with censored data was 36·6 months (IQR 34·1-40·3) for olaparib plus abiraterone and 36·5 months (33·8-40·3) for placebo plus abiraterone. Median overall survival was 42·1 months (95% CI 38·4-not reached) with olaparib plus abiraterone and 34·7 months (31·0-39·3) with placebo plus abiraterone (hazard ratio 0·81, 95% CI 0·67-1·00; p=0·054). The most common grade 3-4 adverse event was anaemia reported in 64 (16%) of 398 patients in the olaparib plus abiraterone and 13 (3%) of 396 patients in the placebo plus abiraterone group. Serious adverse events were reported in 161 (40%) in the olaparib plus abiraterone group and 126 (32%) in the placebo plus abiraterone group. One death in the placebo plus abiraterone group, from interstitial lung disease, was considered treatment related. INTERPRETATION: Overall survival was not significantly different between treatment groups at this final prespecified analysis. FUNDING: Supported by AstraZeneca and Merck Sharp & Dohme.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Saad F, Clarke NW, Oya M, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023. PMID: 37714168. doi:10.1016/S1470-2045(23)00382-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。